Difference between revisions of "Paroxetine-dosulepine"
From Psychiatrienet
| Line 3: | Line 3: | ||
| to = dosulepine | | to = dosulepine | ||
| stop = | | stop = | ||
| − | + | {{stopParoxetine}} | |
| − | |||
| − | |||
| start = | | start = | ||
| − | * '''Day | + | * '''Day 9:''' start administration of dosulepine in a low dosage of 50 mg/day. |
| − | * '''Day | + | * '''Day 16:''' increase administration of dosulepine. |
| info = | | info = | ||
* Paroxetine possibly slows the metabolism of dosulepine via CYP2D6. | * Paroxetine possibly slows the metabolism of dosulepine via CYP2D6. | ||
| − | |||
}} | }} | ||
Revision as of 14:09, 28 October 2015
| ||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||
Switch medication from paroxetine to dosulepine.[1] [2]
Stop paroxetine - Before day 1: gradually reduce dosage of paroxetine to a maximum of 20 mg/day when this dosage is > 20 mg/day.
- Day 1: reduce dosage of paroxetine to a maximum of 10 mg/day.
- Day 8: stop administration of paroxetine.
Start dosulepine- Day 9: start administration of dosulepine in a low dosage of 50 mg/day.
- Day 16: increase administration of dosulepine.
More information- Paroxetine possibly slows the metabolism of dosulepine via CYP2D6.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
